Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
University of Toronto
CompanyRelated News
Study Identifies Distinct Molecular Subtypes of Progressive Supranuclear Palsy
Researchers at the University of Toronto have discovered that progressive supranuclear palsy has distinct molecular subtypes based on tau protein distribution, opening pathways for precision medicine approaches to treat this fatal neurodegenerative disease.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06229418 |
Developing and Testing Drone-Delivered AEDs for Cardiac Arrests In Rural America |
RECRUITING | NA |
| NCT03825835 |
30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants |
RECRUITING | NA |
| NCT02301767 |
MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study |
ACTIVE_NOT_RECRUITING |